Inclusion Criteria:  Patients> 50 years old diagnosed with neovascular age related macular degeneration, Patients who have never received anti-VEGF treatment, Patients who started intra-vitreous injections of ranibizumab between 01 January 2014 and November 30, 2019, Treatment by "treat-and-extend" directly after the loading dose of ranibizumab, Availability of the medical file reporting treatment with ranibizumab.  Exclusion Criteria:  Participation in an interventional clinical study during treatment with ranibizumab, Patients suffering from ocular pathologies and having required surgery during the first 24 months of treatment with ranibizumab (for example advanced glaucoma or cataract).